Hanmi Pharmaceutical, Boehringer Ingelheim deal

Boehringer returned rights to olmutinib ( HM61713) to Hanmi, terminating the partners’ 2015 deal for worldwide development of the compound outside South Korea, China and Hong Kong. According to Boehringer, the Korean Ministry of Food and Drug Safety reported three serious skin reactions, including one fatal case, in a drug safety letter for the candidate. Boehringer said that the ministry’s letter described two cases of toxic epidermal necrolysis and one non-fatal case of Stevens-Johnson syndrome. The company said the toxic epidermal necrolysis was reported in the Phase I/II HM-EMSI-101 trial and the Phase II HM-ESMI-102 trial. Both trials are evaluating olmutinib to treat non-small cell lung cancer (NSCLC). ...